Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878199 · ClinicalTrials.gov registry record · Phase 1
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03878199 is a Phase 1 study that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT03878199, a Phase 1 study, was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given for leukemia in small fat-based particles (liposomes) to improve the drug getting into cancer cells. Giving ruxolitinib and CPX-351 may work better in treating patients with secondary acute myeloid leukemia compared to CPX-351 alone.
Interventions
- DRUG Ruxolitinib
- DRUG Liposome-encapsulated Daunorubicin-Cytarabine
- PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-02-20 |
| Est. Completion | 2025-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878199
The ClinicalTrials.gov registry entry for NCT03878199 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ruxolitinib is the first listed.
NCT03878199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03878199 about?
NCT03878199 is a clinical study titled "Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms". This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for...
What is the current status of trial NCT03878199?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-02-20. Estimated completion is 2025-02-27.
What interventions are being tested in trial NCT03878199?
The interventions under investigation include: Ruxolitinib (DRUG), Liposome-encapsulated Daunorubicin-Cytarabine (DRUG), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT03878199?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.